Good afternoon, everyone, and thank you for joining the PetMed Express Second Quarter Earnings Conference Call. My name is Shamali, the operator for today's call. I would now like to pass the conference over to our host, Mr. Brian Prenoveau, Investor Relations. Sir, the floor is now yours.

Thank you, operator. I'd like to welcome everybody here today to the PetMed Express Fiscal Second Quarter Earnings Call. I would also like to remind everyone that the first portion of this conference call will be listen-only until the question-and-answer session, which will be later in the call. Also, certain information that will be included during this call may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934 as amended that may involve a number of risks and uncertainties. These statements are based upon our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual results could differ materially from those projected. There can be no assurance that any forward-looking results will occur or be realized. And nothing contained in this presentation is or should be relied upon as a representation or warranty as to any future matter, including any matter in respect of the operations or business or financial condition of PetMeds. PetMeds undertakes no obligation to update publicly these forward-looking statements based on subsequent events, except as may be required by applicable law, regulation or other competent legal authority. We have identified various risk factors associated with our operations in our most recent annual report and other filings within the Securities and Exchange Commission. Also, during the course of today's call, the company will be discussing one or more non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in the press release we issued this afternoon. Now let me introduce our CEO and President, Matt Hulett. Matt?

Thank you, Brian. Thank you to everyone for making the time today to participate in our earnings call. For today's earnings call, I would like to focus my remarks on our operational advancements and overall progress. For the quarter ending September 30, 2023, PetMeds delivered sales of $71 million compared to sales of $65.4 million in the prior year, an increase of 9% year-over-year, reflecting our recent acquisition of PetCareRx. Our AutoShip & Save and PetPlus programs grew to 51% of our revenue during this last fiscal quarter, a substantial increase from 39% of revenue for the same time last year. Later in the operating section, we will be discussing the significant improvements that we are making to the platform and program. This quarter delivered our fourth consecutive quarter of year-over-year growth in new customers. We added 75,600 new customers during the quarter, representing a 25% increase year-over-year. This growth includes new customers from the core PetMeds business as well as the contribution from the addition of PetCareRx's new customers. While we were excited about the sequential growth in new customers, we continue to face challenges with stabilizing the core PetMeds returning customer base. Returning customers accounted for sales of $62.4 million during the quarter, reflecting growth of 4.5% year-over-year. However, this growth was solely attributable to the addition of the PetCareRx business. While we do not break out our sales between the core PetMeds and PetCareRx brands, the returning PetMeds customer base is still declining at approximately the same single-digit rate from the previous quarter. And while this decline is less than it was a year ago, we have not yet achieved a stabilized returning customer base. Stabilizing the core returning customer base remains a top priority for us. We believe the combination of selling more consumable products to…

Thanks, Matt. Today, I will report our Q2 fiscal 2024 results for the quarter ending September 30, 2023. As a reminder, this will be the second quarter of combined results including the acquisition of PetCareRx as compared to results for PetMeds only for Q2 fiscal 2023. Next slide, please. Second quarter sales were $71 million compared to sales of $65.4 million in the same period last year, growth of 9% year-over-year. This growth was due to the incremental sales from the acquisition of PetCareRx, increased PetMeds legacy new order sales, partially offset by declines in PetMeds legacy reorder sales. As Matt previously mentioned, we continued our trend of net new customer growth year-over-year, both organically with growth in PetMeds legacy new customer sales and inorganically with the combination of PetCareRx. However, we continued to experience a single-digit decline in PetMeds legacy reorder sales. This decline was relatively flat to the decline in the prior quarter. We welcomed approximately 65,600 new pet parents this quarter compared to 60,700 in the prior year. This represents new customer growth of 25% year-over-year and reflects both organic and inorganic growth. In addition, reorder sales of $62.2 million for the quarter increased 4.5% compared to the reorder sales of $59.7 million in the same period last year. The growth can be attributed to the acquisition of PetCareRx, partially offset by declines in PetMeds legacy reorder sales. With the acquisition of PetCareRx, we also added $2.4 million of revenue associated with our PetCareRx membership programs. We've continued to grow our recurring revenue, including AutoShip & Save sales and PetCareRx membership sales as a percentage of total sales. This drives greater engagement and strengthens our recurring sales base. As Matt mentioned, recurring sales as a percentage of total sales was 51% in the quarter, up sequentially from…

In summary, PetMeds is in an important and promising phase of growth and transformation. We're not just a single category pet prescription business anymore. We're evolving into a comprehensive pet health brand. Four pillars anchor this vision: medication, care, nutrition and wellness. Our focus on newly-acquired partnerships and assets that allows us to offer a wider product range and recurring services to our core customer base, reinforcing us as the brand deeply committed to overall pet wellness. We are about to deploy our new infrastructure with new order management platform improvements and upgraded AutoShip & Save program and added features like VetLive and integrated insurance to offer an unmatched pet parent experience. Plus, our expanded product catalog with top-tier brands like Purina and Royal Canin promises even more growth. We are confident that these investments culminate in increasing the overall value that we provide to our customers. More frequent recurring interactions, combined with a broader set of products and services, will equate to a more stabilized core PetMeds business, as well as offer a platform for new growth. We're thrilled about the strides we've made and even more excited for what's ahead. This transformation isn't just good for us. It's great for our over 2 million pet parents and their fur babies. With these statements, we conclude our prepared remarks for today. Operator, we are now prepared to take questions. Thank you.

[Operator Instructions] And our first question comes from the line of Ryan Meyers with Lake Street Capital.

First one for me. I wonder if you could just provide us with a little bit of commentary on what new customer spend looks like relative to legacy customers, as you guys call it. Just want to kind of get an understanding if we're starting to see some of this cross-selling take place. I know you just added Purina, you talked about Royal Canin. Just want to try to get a good understanding as far as these new customers that are coming onto the platform. Are they starting to purchase adjacent products? Just trying to get a good understanding there would be helpful.

I can take that one, Ryan. Thanks for the question. Yes, just a couple of things to unpack from your question. One is really our food go-to-market in terms of introducing food at scale to our overall base really just started this quarter, and that includes awareness campaigns in our packaging, e-mails, customized offers. And that's kind of statement one. Statement two, really, we do see the introduction of food starting to take hold for new customers. Since those customers are targeted primarily on AutoShip offers, we have the opportunity to attach food when we have that first initial transaction with those customers. So we are seeing some traction with new customers. And then for returning customers, as we start positioning ourselves as a broader pet health expert, it's going to take some time to get the awareness up that we're a brand that introduces something other than prescription medication. But we're really excited about some of the early signals that we've seen.

Got it. That's helpful. And then now with the dividend gone, what's your guys' #1 priority here as far as capital allocation goes forward? And where do you think, now that you don't have to pay that dividend, you can put some more money back in the business? It would be helpful to understand that.

Yes. Ryan, thanks so much for the question. So as you know, we fundamentally believe in the continued growth in the pet e-commerce sector, and reallocating capital will give us this financial flexibility to really aggressively pursue opportunities in this space. So we believe that the reinvestment will provide returns to our shareholders in the long term. And as you know, we're really in the midst of implementing this comprehensive growth strategy that will give us the opportunity to invest in those technological advancements, product diversification, and really take advantage of this growing e-commerce market. We also want to ensure that we have the cash for working capital, to ensure, as we scale and grow, that we can run smoothly, and we have the CapEx options that will help fuel growth.

And our questions and answers portion of the call has ended. I would now like to turn the call back to Matt Hulett, the company's CEO, for his concluding remarks.

Thank you for joining our call today. I'm confident that the future we envision for PetMeds, along with the foundation that we've been laying, will meet the market opportunity in unique and innovative ways and will lead to increased operating results and shareholder value. PetMeds' brand, expertise and reputation are unparalleled. We have greatly accelerated our operating road map. And we look forward to sharing our progress as we go to market with products and services that positively change the lives of our pet parents and pets. Thank you for your continued support.

And this concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.